Typically, KRAS-mutated tumor cells tend to present elevated ferroptosis suppressor protein 1 (FSP1) expression due to the activation of the MAPK-NRF2 signaling downstream of KRAS, leading to significantly enhancement in their anti-oxidative capacity for eliminating ferroptosis-associated lipid peroxides 82. The gene discussed is KRAS; the disease is neoplasm.